Ignite Creation Date:
2024-05-06 @ 1:52 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04140487
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2019-08-19
Brief Title:
Azacitidine Venetoclax and Gilteritinib in Treating Patients With RecurrentRefractory FLT3-Mutated Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia or High-Risk Myelodysplastic SyndromeMyeloproliferative Neoplasm
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-17
Start Date Type:
ACTUAL
Primary Completion Date:
2025-09-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-09-01
Completion Date Type:
ESTIMATED
First Submit Date:
2019-08-19
First Submit QC Date:
October 24 2019
Study First Post Date:
2019-10-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-22
Last Update Post Date:
2024-07-03
Last Update Post Date Type:
ACTUAL